| Document |
Document Title |
|
WO/2014/202703A1 |
The present invention relates to novel strobilurine type compounds I, processes for preparing these compounds, a use of compounds of the formula I and/or their agriculturally useful salts for controlling phytopathogenic fungi, to composi...
|
|
WO/2014/176636A9 |
The invention provides compounds of Formula (I), and methods of treating or preventing a bacterial infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufactur...
|
|
WO/2014/192823A1 |
Provided is a urea synthesis method of excellent reliability and productivity, the method minimizing the amount of oxygen used as an anti-corrosion agent without using a special two-phase stainless steel. In the urea synthesis device, wh...
|
|
WO/2014/183221A1 |
Resveratrol analogs and their use to inhibit Kv1.5 channels are provided. The resveratrol analogs are useful in the treatment of atrial arrhythmias, including atrial fibrillation (AF). Exemplary resveratrol analogs are compounds of gener...
|
|
WO/2014/184116A1 |
The invention relates to new carbodiimides having terminal urea and/or urethane groups of formula (I), wherein R can be the same or different and is selected from the group of the -NHCONHR', -NHCONR'R'', and -NHCOOR''' residues. The inve...
|
|
WO/2014/184248A2 |
Compounds of Formula (I), pharmaceutically acceptable salts thereof, diastereomers, enantiomers, or mixtures thereof: wherein R1, R2, R3, X, Yn and A are as defined in the specification, as well as pharmaceutical compositions including t...
|
|
WO/2014/176636A1 |
The invention provides compounds of Formula (I), and methods of treating or preventing a bacterial infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufactur...
|
|
WO/2014/174745A1 |
Compared to a traditional Eg5 (KSP: kinesin spindle protein) inhibitor, this water-soluble polycyclic compound or a pharmacologically acceptable salt thereof has a greater solubility in an aqueous solvent and has Eg5 inhibitory activity ...
|
|
WO/2014/158654A1 |
Compounds of formula (II): wherein A, R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well...
|
|
WO/2014/150646A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2014/146995A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2014/118556A3 |
Sphingosine 1-phosphate (S1P) is involved in hyper-proliferative diseases, such as cancer and vascular remodeling in pulmonary arterial hypertension. Inhibitors of sphingosine kinase 1 and 2 (SK1 and SK2), which catalyze the synthesis of...
|
|
WO/2014/140238A1 |
The invention relates to a modified allophanate compound bearing acrylate functions, resulting from the reaction of a particular allophanate with an ester from the reaction between an acid selected from acrylic acid and methacrylic acid ...
|
|
WO/2014/143561A1 |
Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may b...
|
|
WO/2014/111102A3 |
The present invention relates to a composition that is effective as a rheology additive and contains 15 - 95% by weight of an oxygen compound (A), 5 - 75% by weight of a urea compound (B), 0 - 50% by weight of an ionogenic compound (C) a...
|
|
WO/2014/138452A1 |
The present invention relates to compounds of formula I or a pharmaceutically acceptable salts thereof; wherein the variables R1-R5, Ar1, and X are as defined herein. The compounds are capable of modulating tyrosine kinase signal transdu...
|
|
WO/2014/114649A1 |
The present invention provides a small molecule inhibitor for adipose triglyceride lipase (ATGL) with the molecule having IC 50 concentrations in the submicromolar range. The inhibitor has the basic structure (I) as disclosed herein and ...
|
|
WO/2014/113607A1 |
Disclosed herein inter alia are compositions and methods useful in the treatment of infectious diseases and exposure to toxins.
|
|
WO/2014/078895A1 |
The present invention relates to new fatty acid analogues and to their use in cancer therapy, including antimetastatic therapy.
|
|
WO/2014/065327A1 |
[Problem] To provide an acrylic or methacrylic compound having a hydroxyl group, and a method for producing the same. [Solution] An acrylic or methacrylic compound having a hydroxyl group represented by formula (1). (In the formula, R1 r...
|
|
WO/2012/116176A3 |
Compounds of Formula (I), known as asymmetric ureas, are useful for preventing and/or treating diseases that are pathophysiologic ally related to the ghrelin receptor in a subject. Method of treating a disease that is mediated by the ghr...
|
|
WO/2014/048547A1 |
The present invention relates to alpha hydroxy amides including compounds of formula (I) and related compounds and their use in the prophylaxis and treatment of inflammatory disorders and diseases, wherein T1, T2, W and Rw has the meanin...
|
|
WO/2014/048700A1 |
The invention relates to a composition comprising components which are selected from A) at least one compound containing at least one carbodiimide group, B) at least one compound containing at least one carboxylic anhydride group, C) opt...
|
|
WO/2013/190509A3 |
Processes for preparing intermediates of Boceprevir and their use in preparation of Boceprevir or its pharmaceutically acceptable salts are provided.
|
|
WO/2014/026845A1 |
The present invention relates to carbamates of formula (I), wherein the variables are defined according to the description, as well as to a process for manufacturing carbamates of formula (I), and to the use of carbamates of formula (I) ...
|
|
WO/2014/022975A1 |
Provided in the present invention are N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methyl phenyl)carbamide and a preparation method for the intermediate thereof. In particular, provided in the present invention is a method for pr...
|
|
WO/2014/016745A1 |
The invention relates to a process comprising: reacting isobutyraldehyde with an aqueous solution of urea in the presence of a phase transfer catalyst to form isobutylidene diurea. Preferably, the phase transfer catalyst is a quaternary ...
|
|
WO/2013/175347A3 |
Disclosed are the compounds of Formula (I) or pharmaceutical acceptable salts thereof, the pharmaceutical compositions comprising an effective amount of compounds of Formula (I), and methods for the treatment of respiratory disorders.
|
|
WO/2013/181697A1 |
The present invention relates to compounds that can be used link substrates to molecules, typically for biological applications such as imaging and the like. The compounds contain a cyclooctyne which is joined, via a linking group, to a ...
|
|
WO/2013/174947A1 |
The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumour-initiating cells. The present inventio...
|
|
WO/2013/152223A2 |
|
|
WO/2013/141163A1 |
Provided is a blocked isocyanate from which the isocyanate group can be easily regenerated even when heated at a low temperature for a short time. The blocked isocyanate is a compound having a group represented by formula (1) or (1'). (X...
|
|
WO/2013/134467A1 |
Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
|
|
WO/2013/130849A1 |
This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the us...
|
|
WO/2013/129121A1 |
The problem to be solved by the present invention is to provide a liquid crystal composition which exhibits little haziness when subjected to liquid crystal alignment and made into a film, and with which cissing can be inhibited when a f...
|
|
WO/2013/127841A1 |
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are defined in the detailed description and claims. In addition, the present invention relates to method...
|
|
WO/2013/115334A1 |
An embodiment of the present invention is a separating agent wherein a group represented by chemical formula (1) or a group represented by chemical formula (2) is introduced to the surface.
|
|
WO/2013/096223A1 |
Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds a...
|
|
WO/2013/091285A1 |
Provided are a urea compound having a structure as represented by general formula I, preparation method thereof, pharmaceutical composition containing the compound, and uses thereof in the preparation of drugs for treating inflammatory r...
|
|
WO/2013/086397A1 |
The present invention relates to compounds, to pharmaceutical compositions comprising the compounds, to a process for making the compounds and to the use of the compounds in therapy. More particularly, it relates to certain glucokinase a...
|
|
WO/2013/082302A1 |
The present invention provides an Agomelatine-urea complex, and a specific crystalline form thereof.
|
|
WO/2013/070600A1 |
The present invention relates to novel aryl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) recep...
|
|
WO/2013/070118A1 |
This invention relates to novel substituted 4,5-diamino-3-alkyloxy- cyclohex-1-ene carboxylic acids, esters thereof or pharmaceutically acceptable salts and/or hydrates, to novel antiviral medicines - inhibitors of the activity of neuram...
|
|
WO/2013/064029A1 |
Provided in the present invention are a benzoylurea derivative of formula (I) with anticancer activity or the pharmaceutically acceptable salt or prodrug thereof, and the preparation of such a derivative and the use thereof in preparing ...
|
|
WO/2013/062947A1 |
The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide ...
|
|
WO/2013/062028A1 |
Provided are a novel compound having an antiviral effect, particularly HIV replication-inhibiting activity, and a medical drug, particularly an anti-HIV drug, containing the same. The compound is represented by Formula (I) (where the bro...
|
|
WO/2013/060889A1 |
The invention relates to oseltamivir derivatives as influenza neuraminidase inhibitors for treating influenza infections and to a method for producing said compounds.
|
|
WO/2013/056559A1 |
Provided are a modified diphenylmethane diisocyanate (MDI) biuret curing agent and preparation method thereof, the curing agent being prepared by reacting dibasic alcohol, water and MDI in an organic solvent; the molar ratio between the ...
|
|
WO/2013/030358A1 |
The invention relates to 4-aminonaphthalene-2-carboxylic acids and 1-amino- isoquinoline-3-carboxylic acids as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compou...
|
|
WO/2013/017714A1 |
The present invention relates to a family of new compounds of general formula (I) that act as low-molecular-weight organogels for a wide variety of solvents and that provide a gel that is very stable at high temperatures. General formula...
|
